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Abstract 
Deep insight into YPEL3. 
YPEL3 identification 
The Yippee gene was first identified in Drosophila 
through a yeast interaction trap screen for proteins 
that interact with Hemolin, a member of the 
immunoglobulin superfamily (Roxstrom-Lindquist 
et al., 2001). Later, five human Yippee-like genes, 
including YPEL3, were described in human and 
mouse tissues (Hosono et al., 2004). YPEL3, also 
known as Protein yippee-like 3, SUAP, RKSG5 or 
MGC10500, was found to be ubiquitously expressed 
in human fetal tissues and to have high sequence 
conservation between a wide ranges of species 
(Roxstrom-Lindquist et al., 2001). Human and 
mouse YPEL3 have 100% sequence identity 
(Hosono et al., 2004). 
In the first publication to address the biology of 
YPEL3, Baker (2003) described a small unstable 
apoptotic protein (SUAP), subsequently determined 
to be YPEL3. Using a murine myeloid precursor cell 
line, apoptosis was induced by IL-3 deprivation and 
granulocyte colony stimulating factor treatment. The 
RNA of these cells was then analyzed. YPEL3 was 
induced in the apoptotic myeloid precursor cells 
compared to normal, growing cells with IL-3 present 
(Baker, 2003). Additionally, YPEL3 was also found 
to be rapidly degraded by the proteasome which led 
to the descriptive name of small unstable apoptotic 
protein. 
YPEL3 gene 
YPEL3 is located in the region of 16p11.2 along with 
22 other genes. The importance of this region in 
relation to development and pathologic syndromes is 
discussed in detail later. The Mammalian Genome 
Project was completed in March 2009. The objective 
of this project was to provide researchers with access 
to sequence-validated full-length protein-coding 
cDNA clones for various mammalian genomes. A 
search for YPEL3 clones on the Mammalian 
Genome Clone Homepage resulted in two clones. 
One denoted as MGC:10500 (Accession: 
BC005009) differs from the YPEL3 sequence by 39 
base pairs according to the GenBank sequence 
alignment. This clone has been determined 
synonymous with YPEL3. However, the GenBank 
records were frozen in 2009 and sequence revisions 
have been performed since then so we have 
performed this analysis through the assistance of 
other tools to verify these results. 
Further investigation through UCSC Genome 
Browser resulted in an 86.33% exon structure 
similarity to the transcript 1 sequence and 100% 
exon structure similarity to the transcript 2 sequence. 
These similarities are based on the BLAT genomic 
alignments of the CDS of the MGC clone with the 
alignments of the RefSeq mRNA CDSs. 
Additionally, the alignment of the mRNA had 100% 
identity with a 95.84% alignment. 











Splign is a tool that is used for accurate and rapid 
alignment of spliced cDNA sequences against their 
genomic counterparts. It has been found to be more 
accurate than a BLAST analysis since BLAST does 
not include the nonaligning intronic segments and 
lacks precision at splice junctions. Using the Splign 
alignment tool through NCBI website inputting 
BC005009 for cDNA and selecting Homo sapiens 
for the whole genome resulted in a 100% match in 
all categories. 
Two functional YPEL3 transcript variants have been 
identified by NCBI. One variant (transcript 2) is a 
940-bp transcript (NCBI Reference Sequence: 
NM_001145524.1) and translates into a 119 amino 
acid protein that is approximately 13.6kDa. This 
isoform is the 'canonical sequence (NCBI Reference 
Sequence: NM_001138996.1). A 1588-bp 
alternative spliced transcript (transcript 1, NCBI 
Reference Sequence: NM_031477.4) has also been 
reported by NCBI. This isoform codes for a 157 
amino acid protein that is approximately 17.5kDa. 
This isoform has an additional 29 amino acids 
sequence at the N-terminus. Both YPEL3 isoforms 
possess 2 putative zinc finger motives that are 
common in all members of the YPEL3 family 
(Hosono et al., 2004). There have been at least 10 
other transcripts identified from different normal and 
tumor human tissues. 
YPEL3 protein structure 
The Yippee gene consists of 4 exons encoding a 
protein of 121 amino acids (13.7 kDa predicted 
molecular weight). Amino acid sequence revealed 
the presence of a zinc binding ring finger domain, a 
motif that is conserved in all yippee homologs. 
While no other protein motifs were uncovered the 
authors did observe using the two-hybrid assay that 
Yippee appeared capable of forming homodimers 
(Roxstrom-Lindquist et al., 2001). 
It has proven difficult to study YPEL3 at the protein 
level for a number of reasons. It is a small protein 
that is rapidly degraded by ubiquitin mediated 
proteasome degradation (Baker, 2003 and personal 
communication Kelly Miller). There is currently no 
published complete structural data and this is an area 
of ongoing research. Attempts are underway to 
purify this protein for additional structural studies. 
YPEL3 protein localization 
The Hosono Lab (2004), using immunofluorescent 
staining in COS-7 cells, found that the YPEL1-4 
proteins localize in the nucleoli and centrosome 
during interphase. During mitosis, YPEL1-4 
proteins were found to localize to an unknown 
structure on or close to the mitotic apparatus and the 
mitotic spindle. Since the antibody used in this study 
was not specific for YPEL3, it is impossible to 
discern the precise location of YPEL3 and the 
resulting localizations could contain any of the 
YPEL 1-4 proteins.  
Unpublished data in the Berberich lab using an 
antibody specific to YPEL3 suggests that YPEL3 
localization is weakly nuclear with punctate 
perinuclear staining.  
Both the localization of YPEL3 and potential 
binding partners of the YPEL3 protein are ongoing 
areas of research. 
YPEL3 and p53 family 
In order to study novel p53 regulated genes, a 
microarray experiment was completed where the 
negative regulators of p53 (Hdm2 and HdmX) were 
silenced in MCF7 breast carcinoma cells using 
siRNA technology (Heminger et al., 2009). MCF7 
cells contain wild-type p53; therefore, knocking 
down Hdm2 and HdmX allowed for the non-
genotoxic stress induction of p53.  
This led to a G1 phase cell cycle arrest along with 
sensitization of the arrested MCF7 cells to DNA 
damage (Heminger et al., 2009). From analysis of 
the microarray data, a novel p53 target was 
discovered named YPEL3. Further validation 
studies, including chromatin immunoprecipitation 
(ChIP), confirmed that YPEL3 is a direct p53 target 
gene (Kelley et al., 2010). TA forms of p63 and p73 
(p53 family members) have been shown to induce 
the YPEL3 promoter (Berberich et al., 2011). The 
biologic relevance of this is an ongoing area of 
research. 






Atlas Genet Cytogenet Oncol Haematol. 2015; 19(7) 486 
 
The expression of p53 varies based on the type of 
stimulus (Purvis et al., 2012). Double-strand DNA 
breaks induces p53 expression in a series of repeated 
pulses. This type of p53 expression allows cells to 
recover from DNA damage. However, when p53 
expression is sustained using a sequence of timed 
drug additions, the cell fate is altered and senescence 
is induced. When p53 expression is sustained 
different downstream genes are targeted mediating 
the senescence response. The Purvis lab sustained 
the p53 signal using Nutlin-3 which binds to p53 
inhibitor Mdm2. They then compared the genetic 
expression levels of various genes after treatments 
with either gamma radiation or Nutlin-3. YPEL3 
expression did not mirror the oscillatory pattern of 
p53 expression and was not induced by p53 pulses. 
Post Nutlin-3 treatment, YPEL3 showed a delayed 
increase in expression under the sustained p53 
signaling. This suggests that as p53 pulses it 
selectively activates genes in response to DNA 
damage and selectively activates a different set of 
genes for terminal cell fates by holding a sustained 
expression level. This substantiates the Berberich 
lab's previous finding that YPEL3 is a crucial gene 
for inducing cellular senescence (Kelley et al., 
2010). 
YPEL3 and p17 
Recently, Klaus Heese (2013) showed that YPEL3 
interacts with p17. p17 is localized in the cellular 
cytoplasm of proliferating cells, where it modulates 
cell survival and drives the cell cycle into the G0/G1 
phase. The significance of this interaction has yet to 
be elucidated. There were also other tumor 
suppressor genes found to interact with p17 in this 
study again implicating YPEL3 in the pathway to 
tumorigenesis. 
YPEL3 and estrogen receptor 
The Cicatiello lab (2010) performed an expression 
profile of ZR-75-1 cells eleven times during a 32 
hour treatment with a physiological dose of 17β-
estradiol. The changes were monitored against 
hormone starved cells. They found deprivation of 
estrogen induced G1 arrest which could be overcome 
by the addition of estrogen. During this 
transcriptome analysis, YPEL3 was found to be 
down regulated after treatment with B-estradiol. It 
was grouped in estrogen cluster 1 with other genes 
found to be suppressed by estrogen. The clusters 
were made to organize the genes according to 
similarities in relative inhibition or activation. 
Cluster 1 includes genes that required 1 to 4 hours of 
hormone treatment for a progressive decrease in 
mRNA expression to be first detected. These results 
were confirmed in an independent microarray study 
previously done by the Finlin lab (2001). 
These findings led to the further investigation of 
YPEL3 regulation by the estrogen receptor. YPEL3 
is down regulated by the estrogen receptor (ER-
alpha) in ER+ breast cancer cells (Tuttle, et al. 2012). 
Additionally, depletion of estrogen or treatment of 
ER+ cells with Tamoxifen leads to induction of 
cellular senescence that is dependent on YPEL3. The 
estrogen receptor regulation of YPEL3 occurred 
independently of p53. This demonstrates yet another 
signaling pathway where YPEL3 plays a crucial role 
and implicates YPEL3 as a tumor suppressor. 
Current studies are underway to investigate the 
relevance of these findings at the protein level in 
human breast tumors. 
YPEL3 and IGF-1 
Insulin and insulin-like growth factor-1 (IGF-1) 
exert specificity on metabolism and growth through 
homologous receptors (Boucher, et al., 2010). 
Several studies have shown that both hormones may 
mediate the same physiological response. However, 
it is not known whether or not insulin receptor (IR) 
and insulin-like growth factor 1 receptor (IGF1R) 
have distinct or overlapping functions. The Boucher 
Lab used several strategies to assess the contribution 
both of these receptors have on gene expression post 
induction by their respective ligands.  
One such strategy included the use of pre and post 
differentiated adipocytes. After a 6 hour treatment 
with IGF-1 in wild-type brown preadipocytes, 
YPEL3 was found to be down-regulated by almost 
75%. They repeated this experiment with insulin 
which mediated similar but lower magnitude of 
genetic expression. In the case of YPEL3, 6 hours 
post insulin treatment decreased YPEL3 expression 
by slightly more than 50%. This data suggests that 
decreased levels of YPEL3 may be required for 
growth to occur, again contributing to the growth 
suppressive role of YPEL3. 
YPEL3 mutations 
The Cancer Genome Atlas has sequenced thousands 
of tumors allowing for the expansion in the 
discovery of genetic mutations (Kandoth, et al., 
2013). The Kandoth Lab analyzed over 3000 tumors 
from 12 cancer types looking for mutated genes in 
order to elucidate the mechanisms of cancer 
initiation and progression.  
They identified four different mutations of YPEL3 
in uterine corpus endometrial carcinoma. Two 
mutations that occurred were silent mutations, and 
two were missense mutations.  
The relevance of these mutations has yet to be 
elucidated. In that only 127 significant mutations 
were found in over 3000 genes, these results suggest 
that the number of mutations required during 
oncogenesis is fairly small and suggest that other 
factors such as epigenetic regulation play a critical 
role for YPEL3 in tumorigenesis. 






Atlas Genet Cytogenet Oncol Haematol. 2015; 19(7) 487 
 
YPEL3 Biologic Functions 
Uncovering the biologic function of YPEL3 is an 
ongoing area of research. The unifying theme is that 
YPEL3 appears to be growth suppressive. Unlike in 
the mouse model with SUAP, induction of YPEL3 
in human tumor (MCF7, U2OS) or primary cells 
(IMR90) did not cause apoptosis, but rather cell 
cycle arrest. Using flow cytometry, there is an 
increase in G1/S phase cells after YPEL3 induction. 
There is also a decrease in colony number in colony 
formation assays after the expression of YPEL3 
(Kelley et al., 2010). Using senescence associated 
beta-galactosidase staining and SAHF (senescence 
associated heterochromatin formation) to assess 
senescence, induction of YPEL3 in MCF7, U2OS 
and IMR90 cells induced senescence (Kelley et al., 
2010). Also, using a Ras-mediated senescence 
model, YPEL3 was shown to act down-stream of 
p53 during Ras-mediated senescence and is required 
for Ras-mediated senescence in IMR90 cells. This 
data supported the conclusion that YPEL3 is a 
growth suppressive gene and further supported a role 
for YPEL3 in tumorigenesis. It is unclear if this 
difference (apoptosis versus senescence) is related to 
the method of expression of YPEL3 or the different 
model system (mouse versus human). 
Rapamycin is known to induce G1 arrest and 
apoptosis (Kasukabe, et al., 2005). Rapamycin has 
been a candidate for cancer therapy; however, the 
different cancer types possess varying sensitivities to 
the growth inhibition effects of Rapamycin. The 
Kasukabe Lab aspired to elucidate a chemical agent 
that when paired with rapamycin would elicit the 
most enhanced growth-inhibitory effects. They 
found that the optimal agent tested was cotylenin A 
which induced growth arrest in G1 phase as well as 
led to induced senescence associated β-gal activity 
rather than apoptosis. In MCF-7 cells after 
rapamycin exposure plus CN-A for 12 hours, YPEL3 
was upregulated 3.72 fold, with just rapamycin 
treatment YPEL3 was induced 2.18 fold, and with 
just CN-A treatment YPEL3 was induced only 2.29 
fold. These results suggest that a synergistic effects 
occurs when Rapamycin and CN-A are used 
together. Additionally, the induction of YPEL3 may 
be involved and required for the SA-β-gal activity 
that was observed after treatment. 
There are a vast amount of nanomaterials in 
consumer products such as: cosmetics, electronic 
appliances, clothes, biomedical applications, and 
solar cells (Park et al., 2013). These nanomaterials 
contain silver (Ag), Copper-doped titanium dioxide 
(Cu-TiO2), and pure titanium dioxide (TiO2). The 
increasing consumption of these materials may 
influence human health. After exposing zebra fish 
embryos to the three different nanoparticles, they 
evaluated expression profiles and selected genes that 
had a fold change of greater than 2 or less than 0.5 
when compared to a control with a p-value of less 
than 0.05. YPEL3 was grouped with the apoptosis 
genes and had a fold change of approximately 3.58 
when embryos were treated with Cu-TiO2. Again, 
suggesting YPEL3 as a growth suppressive gene. It 
was suggested that genes in the apoptosis category 
may also have other functions such as endocytosis 
and immune responses; however, further studies are 




YPEL3 is located in the region of 16p11.2 along with 
22 other genes. It has been previously shown that 
duplication or disruption of this interval may 
contribute to neurodevelopmental disorders such as: 
autism, mental retardation, and schizophrenia. The 
high recurrence of rearrangements of this region may 
be mediated by low copy repeats that make this 
region susceptible to non-allelic homologous 
recombination. Recently, it was reported that a 
patient who suffered from infantile seizures and 
symptoms with malignant migrating partial seizures 
of infancy had de novo microduplications in the 
16p11.2 region (Bedoyan, et al., 2010). This 
suggests that disruption of YPEL3 may have a role 
in infantile seizures. 
Deleted or duplicated intervals of the genome are 
known as copy number variant regions (CNVs). 
They cause a plethora of diseases from autoimmune 
disease to speech and developmental delays and 
autism. The Blaker-Lee lab (2012) analyzed the 
activity of CNV genes in region 16p11.2 in zebra 
fish. Utilizing antisense morpholino 
oligonucleotides (MO) injected into embryos, they 
analyzed the loss of function of 21 genes. Twenty-
four hours after fertilization they examined the 
embryos and scored the brain for various 
development features. They found that the loss of 
several genes, including YPEL3, resulted in the 
formation of a straight midbrain with the hinge point 
absent. Embryos that experienced loss of YPEL3 
function had a wider midbrain-hindbrain boundary 
when compared to control embryos. Additionally, 
the loss of YPEL3 led to a unique hindbrain and 
midbrain-hindbrain boundary phenotype when 
compared to the phenotypes generated by the loss of 
other genes. Co-injection of human YPEL3 cDNA 
with the YPEL3, MO restored the phenotype 
ameliorating both morphological and behavioral 
defects previously observed with the loss of 
function. These results suggest that YPEL3 is very 
active in and required for early for both brain and 
body development. In addition to aberrant brain 
development, the loss of YPEL3 also led to 
movement and axon tract deficiencies. Loss of 
YPEL3 led to abnormal muscle activity; although, 
the axon tract appeared normal, suggesting a 
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potential defectiveness in the synaptic transmission. 
These results suggest the YPEL3 may be important 
in normal neuro-development. 
YPEL3 regulation/methylation 
DNA methylation is one well known method of 
epigenetic regulation of various genes. Given that 
YPEL3 gene expression was determined to be 
decreased in colon tumor samples compared to 
patient matched control DNA (Tuttle, et al., 2011), 
the possibility of DNA hypermethylation was 
considered as the mechanism.  
These authors found that DNA hypermethylation of 
the CpG island has no role in the regulation of 
YPEL3. They did suggest some potential role for 
histone acetylation which has yet to be further 
studied. 
Epigenetic regulations may be responsible for the 
connection between susceptibility to disease and 
environmental exposure (Pascual, et al., 2011). One 
epigenetic regulation that occurs during intrauterine 
growth is DNA methylation. Studies have shown 
that mice possess enhanced sensitivity of allergic 
diseases when they are exposed to diets high in 
methyl donors during pregnancy. Thus, the Pascual 
lab compared B lymphocytes from allergic 
asthmatic, type I hypersensitive patients with 
patients that had bronchial asthma, nasal polyps, and 
an intolerance to aspirin (a non IgE form of 
hypersensitivity), and a control population that had 
no known evidence of allergies. In a listing of genes 
that are most differentially methylated between 
allergic and control groups by HELP assay, YPEL3 
had a 1.56 fold reduction in methylation with a p-
value of 0.0151. Further investigation of the 
relevance of this finding to allergic disease has yet to 
be uncovered. 
Curcumin, a dietary compound, has been found to 
suppress cell proliferation, induce apoptosis, and 
inhibit metastasis (Skommer et al., 2007). Due to its 
tumor suppressing functions, it has been critical to 
elucidate the mechanisms behind the anticancer 
properties of curcumin. After exposure to curcumin, 
YPEL3 gene expression was reduced by slightly 
over 50%, after a 36 hour treatment in HF4.9 cells. 
This is actually inverse to the prediction that YPEL3 
expression would be increased in growth suppressive 
conditions. The authors did not further investigate 
the molecular mechanism for the decreased 
expression of YPEL3 under these conditions. There 
is also no protein level data under these conditions; 
therefore, the biologic relevance of the finding is 
unknown. 
YPEL3 Expression in Tumors: 
Oncomine is a cancer-profiling database that 
contains data that has been analyzed and 
standardized by Compendia Bioscience.  
This database includes data from over 500 cancer 
types that includes changes in genetic expression and 
DNA amplification from over 40,000 experiments.  
When YPEL3 was examined using Oncomine it was 
immediately observed that YPEL3 is 
underexpressed in a variety of cancer types.  
These results substantiate previous findings that 
YPEL3 is downregulated in both lung and colon 
cancer (Tuttle, et al., 2011).  
These results support the hypothesis that YPEL3 is a 
novel tumor suppressor due to its significant 
underexpression in a variety of cancer tumors. 
 
 
Figure 1: An overview of the expression level of YPEL3 in 
Cancer vs. Normal in various Cancer Types. The Following 
Parameters were set: Fold Change-2, P-Value-1E-4, Gene 




Additionally, pancreatic cancer, is associated with 
rapid death and low survival rates due to the inability 
to detect it in the early stages. Pancreatic cancer 
often metastasizes to the liver, among other 
locations. Varying genetic expression has an impact 
on metastatic potential. When NOG 
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(NOD/SCID/γcnull) mice were injected with 
metastatic cell populations derived from BxPC-3 
cells, a human pancreatic cancer, a highly metastatic 
line (LM-Bx-PC-3) was generated (Suemizu, et al., 
2007). Analysis of the expression profiles between 
Bx-PC-3 and LM-BxPC-3 resulted in 9 candidate 
genes having altered expression profiles. These 9 
genes were analyzed in 6 other human pancreatic 
cancer cell lines. YPEL3 was one of the genes found 
to be over expressed in LM-BxPC-3 when compared 
to the parental BxPC-3 line. The 7 fold increase in 
expression level was validated by RT-PCR. These 
results suggest that YPEL3 may play a role in 
pancreatic cancer-liver metastasis. 
Gene expression analysis in elderly patients with 
acute myeloid leukemia was complete by Home and 
colleagues in 2010. Following an mRNA microarray 
analysis from 67 adult myeloid leukemia patients 
ranging in age from 17-80 years old, it was found 
that YPEL3 had a 0.436 positive correlation, 
meaning age related change in expression of YPEL3 
mRNA in AML blasts was identified. Again, the 
relevance of this at the protein level, to the disease 
process or prognosis has yet to be studied. 
Conclusion 
YPEL3 has been uncovered as a p53 target gene with 
growth suppressive properties. It has been shown to 
induce senescence and apoptosis under various 
conditions. Given the down-regulation of this gene 
in various human tumors, it makes it a nice potential 
molecular target for anti-cancer therapies. There is 
much investigation that remains including more 
protein level studies to determine if the gene related 
changes that have been uncovered translate to 
similar protein level findings and finally biologic 
functions. There is also interesting data to suggest 
that YPEL3 may also be a molecular marker for 
disease diagnosis and/or prognosis. This is another 
exciting area of investigation which may have 
impact on future clinical practice. 
Special thanks to Dr. David Hitch for critical review 
and Dr. Steven Berberich for the opportunity to 
complete this work. 
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